SG47877A1 - Use of tetrahydrocarbazone derivatives as 5HT receptor agonists - Google Patents

Use of tetrahydrocarbazone derivatives as 5HT receptor agonists

Info

Publication number
SG47877A1
SG47877A1 SG1996004938A SG1996004938A SG47877A1 SG 47877 A1 SG47877 A1 SG 47877A1 SG 1996004938 A SG1996004938 A SG 1996004938A SG 1996004938 A SG1996004938 A SG 1996004938A SG 47877 A1 SG47877 A1 SG 47877A1
Authority
SG
Singapore
Prior art keywords
tetrahydrocarbazone
derivatives
receptor agonists
agonists
receptor
Prior art date
Application number
SG1996004938A
Other languages
English (en)
Inventor
Alberto Julio Kaulmann
Francis David King
Laramie Mary Gaster
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG47877(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SG47877A1 publication Critical patent/SG47877A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996004938A 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5HT receptor agonists SG47877A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments

Publications (1)

Publication Number Publication Date
SG47877A1 true SG47877A1 (en) 1998-04-17

Family

ID=10697363

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004938A SG47877A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5HT receptor agonists

Country Status (34)

Country Link
US (2) US5464864A (en, 2012)
EP (1) EP0591280B1 (en, 2012)
JP (1) JP3261502B2 (en, 2012)
KR (1) KR100251571B1 (en, 2012)
CN (1) CN1034072C (en, 2012)
AP (1) AP344A (en, 2012)
AT (1) ATE170746T1 (en, 2012)
BR (2) BR9206237A (en, 2012)
CA (1) CA2113726C (en, 2012)
CZ (3) CZ282327B6 (en, 2012)
DE (2) DE69226953T2 (en, 2012)
DK (1) DK0591280T3 (en, 2012)
FI (1) FI103967B1 (en, 2012)
GB (1) GB9113802D0 (en, 2012)
HU (1) HU218907B (en, 2012)
IE (1) IE922062A1 (en, 2012)
IL (4) IL117105A (en, 2012)
LU (1) LU90939I2 (en, 2012)
MA (1) MA22563A1 (en, 2012)
MX (1) MX9203444A (en, 2012)
NL (1) NL300103I2 (en, 2012)
NO (2) NO304774B1 (en, 2012)
NZ (1) NZ243288A (en, 2012)
PL (3) PL169392B1 (en, 2012)
PT (1) PT100620B (en, 2012)
RU (1) RU2137474C1 (en, 2012)
SA (1) SA92130141B1 (en, 2012)
SG (1) SG47877A1 (en, 2012)
SI (1) SI9200125B (en, 2012)
SK (3) SK280907B6 (en, 2012)
TW (1) TW214544B (en, 2012)
UA (1) UA41254C2 (en, 2012)
WO (1) WO1993000086A1 (en, 2012)
ZA (1) ZA924658B (en, 2012)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
AU2002338726B2 (en) * 2001-09-28 2007-03-15 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
RU2340619C2 (ru) 2002-06-21 2008-12-10 Сувен Лайф Сайенсиз Лимитед Новые тетрациклические арилсульфонилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
ES2336664T3 (es) 2002-06-21 2010-04-15 Suven Life Sciences Limited Arilaquil indoles que tienen afinidad por receptores de serotonina utiles como agentes terapeuticos, procesos para su preparacion y composiciones farmaceuticas que los contienen.
AU2003237599B2 (en) 2002-11-28 2009-06-18 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
PT1567492E (pt) 2002-11-28 2013-07-22 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxi-indóis
KR100739987B1 (ko) 2002-12-18 2007-07-16 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 테트라사이클릭 3-치환인돌
RU2430088C2 (ru) * 2004-07-14 2011-09-27 Центарис Гмбх Производные тетрагидрокарбазола и фармацевтическая композиция на их основе
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
JP5220013B2 (ja) * 2006-08-07 2013-06-26 アクテリオン ファーマシューティカルズ リミテッド （３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2011050140A1 (en) 2009-10-22 2011-04-28 Blue Fury Consulting, L.L.C. Posterior cervical fusion system and techniques
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
EP2734634B1 (en) 2011-07-22 2019-08-21 The University of Chicago Igf-1 for use in the treatment of migraine
CA2895816C (en) 2012-12-21 2021-02-23 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
WO2025038666A2 (en) * 2023-08-13 2025-02-20 GATC Health Corp Compounds and methods for treating addiction
CN119499195A (zh) * 2024-11-26 2025-02-25 青岛国信制药有限公司 一种快速吸收琥珀酸呋罗曲坦片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4172834A (en) 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
PL169392B1 (pl) 1996-07-31
NL300103I1 (nl) 2002-12-02
NO2005011I1 (no) 2005-05-18
SI9200125B (en) 2001-12-31
AU1977592A (en) 1993-01-25
DE69226953T2 (de) 1999-05-12
CA2113726A1 (en) 1993-01-07
NO934800L (no) 1993-12-23
TW214544B (en, 2012) 1993-10-11
NL300103I2 (nl) 2003-02-03
EP0591280B1 (en) 1998-09-09
IL117104A (en) 1997-09-30
CZ150696A3 (en) 1997-06-11
CZ282083B6 (cs) 1997-05-14
CN1034072C (zh) 1997-02-19
DK0591280T3 (da) 1999-02-15
GB9113802D0 (en) 1991-08-14
NO934800D0 (no) 1993-12-23
EP0591280A1 (en) 1994-04-13
NO2005011I2 (no) 2008-02-11
IL117105A0 (en) 1996-06-18
SA92130141B1 (ar) 2005-12-18
IL117105A (en) 1998-01-04
WO1993000086A1 (en) 1993-01-07
FI935842A0 (fi) 1993-12-23
FI935842A7 (fi) 1993-12-23
FI103967B (fi) 1999-10-29
ATE170746T1 (de) 1998-09-15
HK1014669A1 (en) 1999-09-30
DE10299042I2 (de) 2005-02-03
CA2113726C (en) 2008-02-19
SK280905B6 (sk) 2000-09-12
HUT68961A (en) 1995-08-28
SK280907B6 (sk) 2000-09-12
IL102322A (en) 1997-09-30
SK280906B6 (sk) 2000-09-12
AP344A (en) 1994-07-05
PL169410B1 (pl) 1996-07-31
JPH06508827A (ja) 1994-10-06
US5637611A (en) 1997-06-10
MX9203444A (es) 1993-12-01
CN1069726A (zh) 1993-03-10
NO304774B1 (no) 1999-02-15
ZA924658B (en) 1993-12-24
DE69226953D1 (de) 1998-10-15
HU218907B (hu) 2000-12-28
DE10299042I1 (de) 2003-02-20
AP9200403A0 (en) 1992-07-31
FI103967B1 (fi) 1999-10-29
UA41254C2 (uk) 2001-09-17
IL102322A0 (en) 1993-01-14
BR9206237A (pt) 1995-04-11
KR100251571B1 (ko) 2000-07-01
JP3261502B2 (ja) 2002-03-04
CZ150596A3 (en) 1997-05-14
CZ282327B6 (cs) 1997-06-11
BR1100460A (pt) 2000-07-18
AU652842B2 (en) 1994-09-08
RU2137474C1 (ru) 1999-09-20
LU90939I2 (fr) 2002-09-24
PL171034B1 (en) 1997-02-28
MA22563A1 (fr) 1992-12-31
CZ286193A3 (en) 1994-07-13
SI9200125A (en) 1992-12-31
IL117104A0 (en) 1996-06-18
PT100620B (pt) 1999-01-29
PT100620A (pt) 1993-09-30
CZ282061B6 (cs) 1997-05-14
SK131993A3 (en) 1994-06-08
IE922062A1 (en) 1992-12-30
NZ243288A (en) 1994-09-27
US5464864A (en) 1995-11-07

Similar Documents

Publication Publication Date Title
SG47877A1 (en) Use of tetrahydrocarbazone derivatives as 5HT receptor agonists
EP0442878A4 (en) Derivatives of tryptophan as cck antagonists
EP0516349A3 (en) 2-hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists
AU4422293A (en) Substituted 2-amidotetralins as melatonin agonists and antagonists
AU4396193A (en) 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
AU5194496A (en) 5-HT4 receptor antagonists
EP0707581A1 (en) INDOLINE DERIVATIVES AS 5 HT2C ANTAGONISTS
AU4873193A (en) Use of substituted benzimidazoles
AU2363492A (en) 5-ht4 receptor antagonists
SG43951A1 (en) Use of indole derivatives as 5HT1 antagonists
AU7579291A (en) Use of purinergic receptor agonists as antineoplastic agents
ZA937505B (en) Imidazopyridine derivatives as 5-HT4 receptor antagonists
ZA929770B (en) Heterocyclic compounds and their preparation and use
HU9400478D0 (en) Process for the preparation of beta-phenylisoserine derivatives and use thereof
AU2654692A (en) Pyrrolobenzoxazine derivatives as 5-ht agonists and antagonists
AU3421493A (en) Use of spiperone or spiperone derivatives as immunosuppressant agents
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
GB9124733D0 (en) Derivatives of poly-4-amino-2-carboxy-1-methyl compounds
HU9501073D0 (en) Benzofuran derivatives as 5-hti-like receptor antagonists
EP0434827A4 (en) Quinolinyl-benzopyran derivatives as antagonists of leukotriene d 4?
AU2790892A (en) Use of suramine and related compounds as contraceptive agents
EP0533056A3 (en) Substituted aminopropanes, process for their preparation and their use as antimycotic agents
AU3769089A (en) Alpha-adrenergic receptor antagonists
IL102539A0 (en) Preparation of 17beta-substituted-4-aza 5alpha-androstan-3-one derivatives
IL106287A0 (en) Receptor derivatives